


Innovations powered by X^{BIO}™ technology

Investor Presentation

Judith Mitchell

Managing Director




NEXT SCIENCE®

NXS at a glance

- Currently the only company in the world with approved products that resolve biofilm based infections in humans
- 3 products in the US human healthcare market
- Additional regulatory approvals of CE Mark and TGA to support revenue growth through market access to Australia, UK, Germany, Netherlands, Nordic countries and France
- True Blue Ocean opportunity for our first in market leave behind infection prevention surgical rinse launching H1 2021

Patients treated with Xbio technology



Key Statistics – November 2020



Treated over 150,000 patients



30 patents awarded

All Products are effective in removing key community acquired pathogens:



- MRSA (golden staph)
- Pseudomonas Aeruginosa
- Candida
- E.Coli

New Products 2021



XPerience Surgical Rinse




Wound Wash

The Science – disrupting the biofilm and eradicating the pathogens “80% of infections in Humans are in a biofilm” (CDC 2011)


The Solution – Xbio™ Technology

Unique non toxic compounds, with no mechanism to create antimicrobial resistance



Deconstruct the bacterial biofilm barrier

Next Science's Xbio technology breaks the ionic bonds that hold the biofilm together. The polymers are then pulled into solution, effectively dissolving the biofilm barrier.



Destroy the bacteria within, through cell lysis¹

With the barrier dissolved, bacteria are exposed and more vulnerable to attack. Bacteria enveloped by Xbio technology experience cell lysis and are destroyed. Cell lysis is non-discriminatory destroying gram-positive and gram-negative bacteria, persister cells, and spores. There is no known resistance mechanism to cell lysis.



Defend from recolonization

The periodic release of bacteria from biofilms has been linked to chronic relapsing infections.² Disrupting and destroying the biofilm barrier can reduce the rate of biofilm recurrence by up to 1,000 times, effectively defending against recolonization.³ Unlike other agents that claim to destroy biofilms, there is no known evidence of bacterial resistance to the Xbio technology.

2020 Milestones before year end

- CE Mark for BlastX to be cleared for sale in Europe
- Distribution agreement for Surface Disinfectant
- XPerience testing finished and submitted to the FDA

2021 First Half Priorities

- XPerience Launch in the US by Next Science
- Bactisure Launch in Europe with Zimmer Biomet
- Pressure Ulcer Program (Wound care) in the US

XPerience Surgical Rinse— Superior Performance



XPerience Surgical Wash is packaged as a sterile solution in a 500mL Polypropylene bag. The solution is used to irrigate the surgical site as a last wash replacing some of the saline rinses.

- Exceptionally effective against all known pathogens
 - MRSA
 - Pseudomonas
 - Candida fungi
 - C.acne
 - E.coli
 - S. epidermis
- Active for > 5 hours

XPerience is addressing an unmet need



XPerience is 10,000,000 times more effective at removing MRSA (Golden Staph)



Investment proposition

Building market awareness - 150,000 patients treated to date, used in >1500 US hospitals

Diversified distribution model for appropriate market conditions to drive and accelerate revenue growth

Proven superiority – exceptionally effective against all known pathogens including COVID-19 & MRSA (Golden Staph)

Leverages the focus of the global trend of increased clean hygiene standards and disease prevention

High margin model - 87% gross margins

30 patents, FDA, CE Mark and TGA regulatory approvals.

XPerience surgical rinse market opportunity \$15B global addressable market

Disclaimer

This presentation has been prepared by Next Science Limited (**Company**) and is provided for general information purposes only. It is not a product disclosure statement, pathfinder document or any other disclosure document for the purposes of the *Corporations Act 2001* (Cth) and has not been, and is not required to be, lodged with the Australian Securities and Investments Commission (**ASIC**). It should not be relied upon by the recipient in considering the merits of the Company or the acquisition of shares in the Company. This presentation should not be considered an offer or an invitation to acquire or sell, or a solicitation to invest in or refrain from investing in, new shares in the Company or any other financial products.

This document has been prepared based on information available as at the date of this presentation. It contains selected summary information and does not purport to be all-inclusive, comprehensive or to contain all of the information that may be relevant or which a prospective investor may require in evaluations for a possible investment in the Company. It should be read in conjunction with the Company's periodic and continuous disclosure announcements which are available at www.nextscience.com and www.asx.com.au. The recipient acknowledges that circumstances may change and that this presentation may become outdated as a result. This presentation and the information in it are subject to change without notice. The Company is not obliged to update this presentation.

The information contained in this presentation does not constitute investment, legal, tax, accounting or financial product advice nor any recommendation to acquire securities in the Company. This presentation has been prepared without taking account of any person's individual investment objectives, financial situation or particular needs. Before making an investment decision, the recipient should consider its own financial situation, objectives and needs, and conduct its own independent investigation and assessment of the contents of this presentation, including obtaining investment, legal, tax, accounting and such other advice as it considers necessary or appropriate. Any references to or explanations of legislation, regulatory issues, benefits or any other legal commentary (if any) are indicative only, do not summarise all relevant issues and are not intended to be a full explanation of a particular matter. The information in this presentation has been obtained from and based on sources believed by the Company to be reliable. Past performance is not an indication of future performance.

This presentation may contain forward-looking statements, guidance, forecasts, estimates, prospects, projections or statements in relation to future matters that may involve risks or uncertainties and may involve significant items of subjective judgement and assumptions of future events that may or may not eventuate (**Forward Statements**). Forward Statements can generally be identified by the use of forward looking words such as "anticipate", "estimates", "will", "should", "could", "may", "expects", "plans", "forecast", "target" or similar expressions. Forward Statements including indications, guidance or outlook on future revenues, distributions or financial position and performance or return or growth in underlying investments are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. No independent third party has reviewed the reasonableness of any such statements or assumptions. None of the Company, its related bodies corporate and their respective officers, directors, employees, advisers, partners, affiliates and agents (together, the **Next Science Parties**) represent or warrant that such Forward Statements will be achieved or will prove to be correct or gives any warranty, express or implied, as to the accuracy, completeness, likelihood of achievement or reasonableness of any Forward Statement contained in this presentation. Except as required by law or regulation, the Company assumes no obligation to release updates or revisions to Forward Statements to reflect any changes. Recipients should form their own views as to these matters and any assumptions on which any of the Forward Statements are based and not place reliance on such statements.

All dollar values are in \$USD unless stated otherwise.

- An investment in Company shares is subject to investment and other known and unknown risks, some of which are beyond the control of the Company, including factors and risks specific to the industry in which Next Science operates as well as general economic conditions, prevailing exchange rates and interest rates and conditions in the financial markets. The Company does not guarantee any particular rate of return on its performance nor does it guarantee any particular tax treatment. Prospective investors should make their own enquiries and investigations regarding all information in this presentation, including the assumptions, uncertainties and contingencies which may affect future operations of the Company and the impact that different future outcomes may have on the Company.
- The distribution of this presentation to persons or in jurisdictions outside Australia may be restricted by law and any person into whose possession this document comes should seek advice on and observe those restrictions. Any failure to comply with such restrictions may violate applicable securities law.
- No party other than the Company has authorised, permitted or caused the issue, submission, dispatch or provision of this presentation, or takes any responsibility for, or makes or purports to make any statement, representation or undertaking in this presentation and there is no statement in this presentation that is based on any statement by any other party. No person, either as a director or partner of, or in the employment of, the Company has any authority to make, imply, or give any representation or warranty whatsoever in relation to the information contained in this presentation. None of the Next Science Parties take any responsibility for any information in this presentation or any action taken by you on the basis of such information. To the maximum extent permitted by law, the Next Science Parties: exclude and disclaim all liability, including (without limitation) any liability for fraud or negligence, for any expenses, losses, damages or costs incurred either as a result of the information in this presentation being inaccurate or incomplete in any way for any reason, or otherwise arising in connection with this presentation; and make no representation or warranty, express or implied, as to the currency, accuracy, reliability or completeness of information in this presentation.

NEXT SCIENCE[®]

Break through biofilm.

investorqueries@nextscience.com | +61 2 8607 5125 | NextScience.com

**Authorised by the Next Science Board
November 18, 2020**

Suite 1902 Tower A
821 Pacific Highway
Chatswood NSW 2067

Additional biofilm education can be found at: [biofilm.healthcare](https://www.biofilm.healthcare)